Navigation Links
First Patient Dosed in Phase I Clinical Trial using RoosterBio’s Cellular Starting Materials
Date:3/4/2020

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today a significant milestone in the regenerative medicine field with the dosing of the first patient using its innovative cellular starting materials. The patient has been treated by RoosterBio’s pharmaceutical customer with an Investigational New Drug (IND) that was manufactured using RoosterBio’s CliniControl cell and media systems. This marks the first demonstration of standardized off-the-shelf cellular starting and ancillary raw materials and associated scalable biomanufacturing applied to regenerative medicine therapeutic products.

“The first-in-human clinical trial of our customer’s novel therapeutic manufactured using our CliniControl products is an important milestone and a key step to tangibly demonstrate RoosterBio’s commitment to helping our customers rapidly develop safe and effective regenerative medicine products,” said Margot Connor, CEO of RoosterBio. “More importantly, this platform advancement will fuel the rapid commercialization of scalable regenerative cures.”

The use of RoosterBio’s CliniControl products is supported by Type II Master Files (MF) which were submitted to the U.S. Food and Drug Administration (FDA) in 2017 for bioprocessing media and 2018 for hMSC banked vials. As a result, the FDA has on-file the proprietary chemistry, manufacturing and controls (CMC) information for RoosterBio’s starting cell banks and bioprocess media systems for simple referencing by its therapeutic sponsors.

RoosterBio now has five customers who have been granted authorization to cross reference both of its MFs as part of their customers’ clinical development. RoosterBio has radically simplified product development and shortened product development timelines by providing access to standardized, off-the-shelf, ancillary and cellular starting materials manufactured under current good manufacturing (cGMP) conditions for further manufacturing and regulatory compliancy. RoosterBio’s focus on industrializing the regenerative medicine supply chain ushers in a new era of productivity to the field.

Connor added, “We are excited to see RoosterBio’s vision of solving regenerative medicine product and process development challenges with innovative biomanufacturing strategies, continue to drive novel therapeutic approaches forward.”

About CliniControl™ Products
CliniControl cells and media are the first and only off-the-shelf, cGMP-produced human mesenchymal stem/stromal cells (hMSCs) and bioprocess media systems with accompanying Type II Master Files on record with the U.S. Food and Drug Administration (FDA). CliniControl products radically simplify the process of IND filing and clinical translation for Regenerative Medicine companies that utilize hMSCs within their manufacturing process.

About RoosterBio, Inc.
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization to the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.

Read the full story at https://www.prweb.com/releases/first_patient_dosed_in_phase_i_clinical_trial_using_roosterbios_cellular_starting_materials/prweb16955951.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Dell Laser Consultants is Among the First in Texas to offer the RxSight™ Light Adjustable Lens to Patients
2. Accelera Canada, a Full-Service Firm, Opens First Office in Toronto
3. First Alzheimer’s Disease Gene Therapy Human Study Provided by Maximum Life Foundation, Offers 10 Free Therapies for Qualifying Patients
4. Personalized Stem Cells, Inc. Announces First Patients Treated in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
5. Burlington Medical Develops the First-of-Its-Kind Radiation Protection Garment Exclusively for Women
6. The first International Sigma Anti-Bonding Calcium Symposium (ISACS 2019) by CBHI
7. Personalized Stem Cells, Inc. Announces First Patients Enrolled in FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells
8. Deep Science Ventures Launches Europe’s First Venture-Building Programme for Food & Agriculture
9. VetStem Biopharma Secures FDA Approval of First Human IND for its Subsidiary, Personalized Stem Cells, Inc.
10. Landsec and Spartan Bioscience Trial the World’s First On-Site Legionella DNA Test in the UK
11. Swiss Biotech Gnubiotics, Announces Global Launch of GNU100 the First Microbiome Specialty Ingredient for Companion Animal Gut Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2020)... ... August 21, 2020 , ... ... has been published and is now available on the company’s global website. ... the X-ray analysis community, presenting current news and crystallographic research. , The ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman Carl ... executive with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and ... Throughout his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, ...
(Date:8/7/2020)... ... August 06, 2020 , ... Nine middle school teachers from ... Program, a unique professional development program that provides advanced STEM (science, technology, engineering ... teachers nationwide. , Created in partnership between the National Stem Cell Foundation and ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... ... August 29, 2020 , ... DuPont ... capability in Wuxi, China. The new plant operation will provide the local animal ... technology. , “This facility will improve the flexibility of our offerings to ...
(Date:8/12/2020)... , ... August 12, 2020 , ... ... (EMMA International), a global leader in FDA compliance consulting has been named ... fastest-growing private companies. The list represents a unique look at the most successful ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... launch of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines ... the globe, requiring fast track capacity to provide patients with urgently needed vaccines ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® Respiratory Gating ... countries, has reached its 20th anniversary of worldwide use. Introduced in the US ... universities including University of Pennsylvania, University of Michigan, University of Maryland, University of ...
Breaking Biology Technology: